Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Directed Change in TNFα Specificity to Create DR5 Antagonists.

Bulletin of experimental biology and medicine - 1 Jul 2018

Ukrainskaya V M, Bobik T V, Argentova-Stevens A, Slutskaya E A, Kalinin R S, Gabibov A G, Stepanov A V

Abstract excerpt

Death receptor 5 (DR5) is a promising target for antitumor therapy due to its high expression on different tumor cells. Resistance of various tumor cells against TRAIL, a natural ligand for the death receptors, reduces its therapeutic potential and prompts the search for novel agonists at these receptors. Previous screening across the combinatorial peptide library yielded a peptide sequence KVVLTHR that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Vectors
Share to Lymphocytes
Share to Protein Conformation, alpha-Helical

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Protein Conformation, beta-Strand

Share to Protein Interaction Domains and Motifs

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Share to Receptors, Tumor Necrosis Factor, Type I

Share to TNF-Related Apoptosis-Inducing Ligand

Source

Identifiers

PMID: 30003423
DOI: 10.1007/s10517-018-4176-9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Directed Change in TNFα Specificity to Create DR5 Antagonists.PMID 30003423Read ↗

Mutations Enhancing Selectivity of Antitumor Cytokine TRAIL to DR5 Receptor Increase Its Cytotoxicity against Tumor Cells.Semantic proximity Read ↗

Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway.Semantic proximity Read ↗

Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding.Semantic proximity Read ↗

Rapid and efficient cancer cell killing mediated by high-affinity death receptor homotrimerizing TRAIL variants.Semantic proximity Read ↗

DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design.Semantic proximity Read ↗

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling.Semantic proximity Read ↗

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5.Semantic proximity Read ↗

Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivoSemantic proximity Read ↗

Apoptosis-Inducing TNF Superfamily Ligands for Cancer TherapySemantic proximity Read ↗

Development and Characterization of a Potent Tumor Necrosis Factor-Alpha Blocking AgentSemantic proximity Read ↗

APG350 Induces Superior Clustering of TRAIL Receptors and Shows Therapeutic Antitumor Efficacy Independent of Cross-Linking via Fcγ ReceptorsSemantic proximity Read ↗

The effect of cisplatin on cytotoxicity of anticancer cytokine TRAIL and its receptor-selective mutant variant DR5-B1.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.